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 NAC-Dex reduced TNF-, IL-8 and ROS on a gut inflammation model. 
 
 NAC-Dex reversed the morphological changes induced by inflammation and 
increased the TEER 




Oral administration of antioxidant and anti-inflammatory drugs have the potential to improve the 
current therapy of inflammatory bowel disease. Success of oral treatments, however, depends on 
the capacity of drugs to remain structurally stable along the gastrointestinal tract, and on the 
feasibility of accessing the target cells. Delivering anti-inflammatory and antioxidant drugs to 
macrophages using targeted nanoparticles, could make treatments more efficient. In this work 
structural features and in vitro activity of macrophage-targeted nanostructured archaeolipid 
carriers (NAC) containing the high antioxidant dipolar C50 carotenoid bacterioruberin (BR) plus 
dexamethasone (Dex): NAC-Dex, are described. Ultra-small (66 nm), -32 mV  potential, 1200 
g Dex /ml NAC-Dex, consisted of a compritol and BR core, covered by a shell of sn 2,3 ether 
linked archaeolipids and Tween 80 (2: 2: 1.2: 3 % w/w) were obtained. NAC-Dex were extensively 
captured by macrophages and Caco-2 cells and displayed high anti-inflammatory and antioxidant 
activities on a gut inflammation model made of Caco-2 cells and lipopolysaccharide stimulated 
THP-1 derived macrophages reducing 65 % and 55 % TNF- and IL-8 release, respectively and 
60 % reactive oxygen species production. NAC-Dex also reversed the morphological changes 
induced by inflammation and increased the transepithelial electrical resistance, partly 
reconstituting the barrier function. Activity of BR and Dex in NAC-Dex was partially protected after 
simulated gastrointestinal digestion, improving the chances of BR-Dex joint activity. Results 
suggest that oral NAC-Dex deserve further exploration as intestinal barrier repairing agent.  
 











Inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, are 
incurable relapsing disorders of the gastrointestinal tract (GIT). IBD are characterized by chronic 
inflammation and epithelial injury induced by the uncontrolled activation of the mucosal immune 
system [1]. The pathogenesis and progression of the inflammatory cascade are attributed to 
genetic, immunological, microbiome, and environmental factors [2, 3]. Oxidative stress (OS) is 
the a major responsible for IBD pathophysiology, rather than a consequence of chronic 
inflammation of the intestinal mucosa [4, 5, 6]. Enhanced production of reactive oxygen and 
nitrogen species (ROS and RNS, respectively) is associated with chronic intestinal inflammation 
in the early stages of IBD, amplification of inflammatory process, destruction of mucosa, 
development of fibrosis [7, 8]. Moreover, the impaired antioxidant activity in IBD patients is known 
to favour the progression of disease [9]. IBD patients require life-long medication and most often 
surgery. Treatments are mainly focused on reducing inflammation with oral sulfasalazine, 
corticosteroids or intravenous infliximab that blocks TNF- [10] or by supressing the immune 
system with thiopurines and cyclosporine. However, the adverse effects associated with these 
drugs used over prolonged periods and the high relapse rate limit their use [10, 11]. Despite of 
the connection between OS and IBD and the fact that co-administration of anti-inflammatory drugs 
and antioxidants has shown clinical benefits in IBD patients [12-14], no specific antioxidant 
treatment against IBD is available. Success of oral treatments, however, depends on the capacity 
of drugs to remain structurally stable along the GI transit, and on the feasibility of accessing the 
target cells. Delivering anti-inflammatory and antioxidant drugs to macrophages and dendritic 
cells with targeted nanoparticles, could make IBD treatments more effective than conventional 
therapies.    
Halophilic archaea produce polar (PA) and neutral archaeolipids (NA) with unique properties, 
different to polar lipids from Eukarya and Bacteria lipids. PA are sn 2,3 saturated isoprenoid 
chains linked via ether bonds to glycerol. Unlike liposomes prepared with phospholipids from 
plants or animal sources (sn 1,2 acyl chains linked to glycerol by ester bonds) archaeosomes 
(ARC) made with PA from halophilic archaebacteria Halorubrum tebenquichense are colloidal 
and chemically resistant to stress such as heat sterilization, storage under cold-free conditions 
[15], nebulization [16] and gastrointestinal digestion [17]. Besides, the main component of H. 
tebenquichense PA, 2,3-di-O-phytanyl-snglycero-1-phospho-(3'-sn-glycerol-1'-methylphosphate) 
(PGP-Me), is a ligand for scavenger receptors class A (SRA1) [16] highly expressed on 
macrophages and dendritic cells. On the other hand, NA consist almost exclusively of 
bacterioruberin (BR), and its precursors (2-isopentenyl-3,4-dehydrorhodopin (IDR), bis-
anhydrobacterioruberin (BABR), and mono-anhydrobacterioruberin (MABR)), together with 
minute amounts of carotene, lycopene and phytoene [18]. BR is a dipolar C50 carotenoid with 
four terminals hydroxyl groups responsible for the red colour of the halophilic Archaea [19]. BR 
acts as cell membrane stabilizer, confers protection against the natural exposition to high UV 
radiation [20], and displays potent antioxidant activity [21, 22]. Different to the C40 carotenoids 
identified in bacteria, algae, fungi, and plants, BR has 13 conjugated double bonds and is highly 
efficient scavenger of RNS, ROS, and quencher of singlet oxygen [23, 24]. Moreover, BR shows 
higher antioxidant, antihaemolytic and anticancer activities than the well-known -carotene [23, 
25, 26]. However, the high hydrophobicity and susceptibility to chemical degradation due to the 
13 conjugated double bonds of the BR, discourages its oral administration.    
Our hypothesis is that combination of BR and Dex in macrophage targeted-gastrointestinal 
resistant nanoparticles could be beneficial for IBD treatment. Hence, here we report the structural 
features and in vitro activity of ultra-small macrophage-targeted nanostructured archaeolipid 
carriers (NAC) having a core loaded with BR extract and Dex,  covered by a PA shell (to confer 
structural endurance, making the nanoparticle suitable for oral administration and macrophages 
targeted [27]). The activity of such nanoparticles (NAC-Dex) was assessed on a gut inflammation 
model, made of Caco-2 cells grown on the apical side and PMA differentiated THP-1 cells grown 
at the basolateral side of cell culture porous inserts membrane stimulated with lipopolysaccharide 
(LPS). Histology, immunohistochemistry and transepithelial electrical resistance (TEER) of the 
gut model as well as release of proinflammatory cytokines IL-8 and TNF- and intracellular ROS 
were determined, in the absence and presence of LPS stimuli. Then, the effect of NAC-Dex on 
the structure of inflamed epithelia and the release of inflammatory cytokines, either before or after 
submitted to a gastrointestinal digestion process was determined and compared with that of Dex 
loaded into conventional nanostructured lipid carriers lacking PA and BR extract (NLC-Dex). 
 









Compritol ATO 888 (Compritol) was a gift from 
Daltosur SRL (Gattefosse). Soybean phosphatidylcholine (SPC, purity >90%) was a gift from 
Lipoid, Ludwigshafen, Germany. Miglyol 840 was a gift from Etilfarma SA, Argentina. 
Dexamethasone (Dex), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) (Trolox), 2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid) (ABTS),), lipopolysaccharides from Escherichia coli 0111:B4 (LPS), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 2- Mercaptoethanol, Phorbol 12-
myristate 13-acetate (PMA), pepsine, bovine serum albumin, Mowiol and 3-(2′-benzothiazolyl)-7-
diethylaminocoumarin (coumarin-6, C6) were from Sigma-Aldrich (MO, USA). 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA), TO-PRO-3 and rhodamine-conjugated 
phalloidin was from Thermo Fisher Scientific, the USA. Tween 80 (T80) was acquired from Merck. 
Porcine pancreatic lipase was a gift from Gador (Biozym). Triton X-100 was from Biopack, 
Argentina. Roswell Park Memorial Institute 1640 (RPMI), Modified Eagle Medium (MEM), 
penicillin-streptomycin sulphate, glutamine, sodium pyruvate and trypsin/ethylenediamine tetra 
acetic acid were from Gibco®, Life Technologies (NY, USA), fetal bovine serum (FBS) was from 
Internegocios, Cordoba, Argentina. The other reagents were of analytic grade from Anedra, 
Research AG (Buenos Aires, Argentina). 
2.2 Archaebacteria growth, extraction, and characterization of polar archaeolipids (PA) 
and BR extract 
Halorubrum tebenquichense archaeas were grown in 15 l basal medium supplemented with 
yeast extract and glucose at 40°C and 600 rpm in a home-made bioreactor and harvested after 
96 h growth. Total archaeolipids were extracted using the Bligh and Dyer method modified for 
extreme halophiles [28], and then separated by cold acetone precipitation into an acetone-
insoluble fraction (polar archaeolipids, PA) and acetone soluble fraction (BR extract). Both 
fractions were dried and stored at -20 °C until used. 
Between 400 - 700 mg PA and 45 - 90 mg BR extract were isolated from each culture batch. 
PA was routinely screened by phosphate content [29], and electrospray-ionization mass 
spectrometry. BR extracts were characterized by UV-visible spectra (300 - 700 nm). BR was 
quantified measuring the absorbance at 490 nm using an average extinction coefficient (E1cm1%) 
of 2660 [30]. Thin layer chromatographic (TLC) analysis of BR extract was performed onto a TLC 
plate (silica gel 60 F254, Merck, Germany) and developed in acetone-petroleum ether (20:80% 
v/v). Individual spots were scrapped off the TLC, eluted in methanol and UV-visible spectra were 
recorded. Chromatographic separation of BR extract was performed on a Finnigan HPLC system 
with photodiode array using C18 Grace Smart RP-18 column (5 m; 150 x 4.6 mm) set at 25 °C 
and detection at 490 nm. The following gradient, at a flow rate of 0.8 ml/min, was performed: 0–
5 min, 85% methanol; 5–105 min, 100% methanol; 90–105 min, 100% methanol; 105-107 min, 
85% methanol; 107-109 min, 85% methanol.  
2.3 Preparation and characterization of Dex-nanoparticles (Dex-NP) 
Nanostructured lipid carriers (NLC) made of compritol: Miglyol: SPC: T80 (2: 2: 1.2: 3 % w/w) 
and nanostructured archaeolipid carriers (NAC) made of compritol: BR extract: PA: T80 (2: 2: 1.2: 
3% w/w) were prepared by the emulsion-ultrasonication method [31]. Briefly, 60 mg compritol and 
60 mg of Miglyol or BR extract (oil phase) were melted at 75-80°C in a water bath. In another 
separate tube, 36 mg of SPC or TPA and 90 mg of T80 were suspended in 3 ml of ultra-pure 
water and heated at 75-80°C. The aqueous phase was dispersed for 30 s using an Ultra 
TurraxT10 Basic (IKA, Germany) and immediately added dropwise into the oil phase at 13,000 
rpm at 75-80°C. This hot oil-in-water emulsion was sonicated with a probe-type sonicator (6 mm 
probe, Sonics& Materials Inc, Vibra Cell Power, USA130 Watt), at 70% amplitude for 10 min. 
Finally, the nano-emulsion was cooled down at 4°C. 
To prepare Dex-NP (NLC-Dex and NAC-Dex), 5 mg Dex were mixed with 120 mg of oil phase 
and processed as stated before. After solidification, NPs were filtered across a nylon syringe filter 
membrane of 1.2 µm pore size to eliminate free Dex. 
To prepare C-6 labelled NPs (NLC-C6 and NAC-C6), 0.3 mg of C6 (0.1 %w/w) were mixed 
with 120 mg oil phase and processed as stated before. After solidification, nanoparticles were 
filtered across a nylon syringe filter membrane of 1.2 µm pore size to eliminate free C6. 
2.3.1 Size and  potential 
Size and  potential of NPs were determined by dynamic light scattering (DLS) and phase 
analysis light scattering (PALS) respectively, using a nanoZsizer equipment (Malvern 
Instruments, Malvern, United Kingdom). To that aim, NP suspension was 20-fold diluted in 








2.3.2 Quantification of dexamethasone 
Dex was quantified by spectrophotometry at 243 nm after complete disruption of 20 µl of NP 
suspension in 3 ml CHCl3:CH3OH (9:1 v/v). Void NP were used as reference. The absorbance of 
the sample was compared to a standard curve prepared with Dex in CHCl3:CH3OH (9:1 v/v).The 
standard curve was linear in the range 0 - 30 µg/ml with correlation coefficient of 0.99.The 
encapsulation efficiency (%EE) was calculated using the following relationship: %EE = (amount 
of drug in the filtrate/amount of drug added) × 100. 
2.3.3 Quantification of coumarin-6 
Spectrofluorometric quantification of C6 was carried out using λEx 465 nm and λEm 490 nm, 
after complete disruption of one volume of NPs in 7000 volumes of CHCl3. The fluorescence 
intensities of the samples were compared to a standard curve prepared with C6 in CHCl3. The 
standard curve was linear in the range 0.05 - 20 ng/ml with correlation coefficient of 0.991. 
2.3.4 Morphology 
Morphology of NPs was studied by transmission electron microscopy (TEM) and cryo-electron 
microscopy (cryo-EM). For TEM, aqueous suspensions of NP were deposited on a carbon grid 
membrane and the grid covered with a drop of 2% w/v phosphotungstic acid. Then, the grids were 
air-dried and analysed using a Jeol 1200-EX II (Tokyo, Japan) instrument. For Cryo-EM: samples 
were prepared in a controlled environment vitrification system (Vitrobot Mark I, FEI, The 
Netherlands) with controlled temperature (22°C) and humidity (100%). Samples were examined 
in Jeol JEM-1400Plus (JEOL, Japan) instrument, operating at 120kV. Image collection were made 
using a CCD camera Gatan Multi Scan 794. Images were not processed after acquisition. Sample 
preparation and data acquisition were performed at the Electron Microscopy Laboratory 
(EML)/Brazilian Nanotechnology National Laboratory (LNNano). 
2.3.5 Thermal analysis 
Calorimetric analysis of physical mixture of lipids and aqueous suspension of NPs were 
performed using a DSC Q200 TA instrument equipped with a Refrigerator Cooling System 
(RCS90). Briefly, 3-5 mg of lipids or NPs suspension was taken in an aluminium pan. DSC scans 
were recorded from -50 °C to 90 °C for aqueous suspensions and from -50 °C to 290 °C for bulk 
material at a heating rate of 10ºC/min, using an empty pan as reference. Melting point and 
enthalpy were calculated using the software TA Universal analysis provided by TA instruments®. 
The recrystallization index (R.I.) was calculated according to the following equation: R.I. (%) = ∆H 
nanoparticles dispersion (J/g)/ [∆H bulk material (J/g) x concentration lipid phase (%)] x 100  
2.3.6 1,1‑Diphenyl‑2‑picrylhydrazyl (DPPH) Radical Scavenging Assay 
DPPH radical scavenging assay was performed as described by Jiménez-Escrig et al. (2000) 
[32] with some modifications. Briefly, 667 µl of 100 M DPPH*+ in methanol was mixed with 83 μl 
of sample in methanol and incubated for 30 min at 37 °C in the dark on an orbital shaker. Then, 
absorbance at 580 nm was measured in a Metrolab 330 spectrophotometer, and the radical 
scavenging capacity (RSA) (%) was calculated as: (Abs negative control -Abs sample)/Abs 
negative control x 100. Where Abs negative control is the absorbance at 580 nm of sample 
prepared with 667 µl of DPPH*+ plus 83 μl of methanol. Calibration curves of Trolox (1.2-10 g/ml) 
and BR extract were done. The inhibitory concentration of the extract providing 50% reduction of 
the radical scavenging activity (IC50) was calculated from a graph built with log RSA (%) against 
BR concentration. 
The antioxidant activity of NAC was measured after extraction of BR in methanol. Briefly, 250 
μl of NPs were mixed with 100 μl of methanol. The mixture was then centrifuged at 9500 g for 10 
min, the supernatant was collected and 100 μl of methanol was added to the pellet. After a second 
centrifugation, the supernatant was mixed with the first one and dried under flux of N2. 
2.4 Stability under gastrointestinal conditions 
2.4.1 Colloidal stability in simulated gastric and intestinal fluid 
The structural stability, and possible aggregation of NPs into simulated gastric fluid (SGF, 3.2 
mg/ml pepsin, 34.2 mM NaCl, pH 1.2) and simulated intestinal fluid (SIF, 150 mM NaCl, 5 mM 
CaCl2, 5 mM sodium taurocholate, 1.25 mM lecithin, 300 UI/ml porcine pancreatic lipase, 0.5% 
SDS in Tris-HCl 10 mM pH 6.8) was measured as reported by Higa et al., 2017 [27]. Briefly, 0.1 
ml of NPs were diluted with 0.9 ml of SGF and incubated at 37ºC during 30 min. After that, pH 
was adjusted to 6.8 using 1 M NaHCO3 and then 1 ml of SIF was added and incubated along 2h 
at 37ºC. Finally, samples were centrifuged for 10 min at 10,000 rpm to remove pancreatic 
aggregates from the fluid. The particle size and  potential after incubation were determined as 
stated above. 







Lipolysis was performed under SIF according to Porter et al, 2001 [33] with minor 
modifications. Briefly, 300 µl of NPs were added into 3 ml of SIF. The mixture was incubated at 
37ºC. The pH was maintained at 6.8 throughout the whole lipolysis process by manual titration 
with 0.2 M NaOH to neutralize the fatty acid produced by the digestion of lipids. The digestion 
process was considered complete when the pH change was less than 0.05 units within a 15 
minutes interval. Cumulative lipolysis percentage versus time profiles of NPs titrated with NaOH 
were plotted. 
2.5 Cell lines and culture conditions 
Caco-2 cells were kindly provided by Dr. Osvaldo Zabal, INTA Castelar, Buenos Aires, 
Argentina. The human monocyte cell line THP-1 (ATCC® TIB-202™) was supplied by Dr. Paula 
Barrionuevo, Academia Nacional de Medicina, Argentina. 
Caco-2 cells were maintained in MEM with 1% sodium pyruvate, supplemented with 10% FBS, 
100 U/ml penicillin 100 g/ml streptomycin and 2 mM L-glutamine and were grown in a humidified 
atmosphere of 5% CO2 at 37°C. THP-1 cells were maintained in complete RMPI medium 
supplemented with 0.05 mM 2-mercaptoethanol and 1 mM sodium pyruvate. THP-1, monocytes, 
were differentiated into macrophages by treatment with 162 nM PMA for 24h. Then, the medium 
was replaced by fresh complete RPMI medium and cells were grown for additional 96 h. The 
expression of the surface marker CD14 associated with macrophage differentiation was detected 
by flow cytometry using monoclonal mouse anti-human antibodies IgG1κ CD14-PE (BD 
Biosciences, San Diego CA, USA). 
2.5.1 Cell viability 
The viability of cells upon 24 h incubation with void and Dex-NP was measured by the MTT 
assay. Briefly, differentiated THP-1 and Caco-2 cells were seeded in 96-well plates at a density 
of 3 × 104 cells per well and grown for 24 h. Then, cells were incubated with series of different 
concentration of empty NP (20; 200 and 2000 µg/ml of Compritol), and Dex-NP (1.7, 17 and 170 
μg Dex /ml - 20, 200 and 2000 µg/ml compritol, respectively). After 24 h of incubation the medium 
was removed, cells were washed with PBS and 110 μl of 5 mg/ml MTT solution was added to 
each well. After 3 hours of incubation, the MTT solution was removed, the insoluble formazan 
crystals were dissolved with 100 μl of dimethyl sulfoxide, and absorbance was measured at 570 
nm in a microplate reader (Dynex Technologies, MRX tc, Chantilly, Virginia). The cell viability was 
expressed as a percentage of the cells grown in medium. 
2.5.2 Cellular uptake 
The uptake of C6- labelled nanoparticles by macrophages and enterocytes was measured by 
flow cytometry. Briefly, Caco-2 cells and differentiated THP-1 cells were seeded on 24-wells 
culture plates at a density of 1.5 x 105 cells per well and grown for 24 h. Then, cells were incubated 
with 20 µg/ml (compritol) NLC-C6 and NAC-C6 in complete medium for different time periods (1, 
3 and 5 h) at 37°C and 4 °C (as a control to determine the unspecific adsorption on cell surface). 
After incubation, the cells were trypsinized, washed with PBS and a total of 1×104 cells were 
analysed by flow cytometry (BD FACSCalibur™; BD Biosciences, San Jose, CA, USA). Data 
were analysed using WinMDI 2.9 software (Microsoft, Redmond, WA, USA). The fluorescence 
was further normalized to the C-6 content of each formulation. 
2.6 Gut inflammation model: co-cultured of Caco-2 and PMA differentiated THP-1 cells 
stimulated with lipopolysaccharides (LPS). 
2.6.1 Co-culture development 
On one hand, Caco-2 cells were cultured on porous membrane inserts for 20 days to acquired 
differential and polarized phenotype, functional and morphological like adsorptive enterocytes. 
Briefly, on day 0 Caco-2 cells were seeded at a density of 1.3 x 105 cells onto ThinCert™ Cell 
Culture Inserts (12 wells, 0.4 µm pore size PET membrane) and grown for 20 days, the culture 
medium was changed every other day.  
On the other hand, to differentiate THP-1 human monocytes into macrophages, 8 x 105 THP-
1 cells per well were seeded on a different 12 well culture plate and induce differentiation with 
PMA as state before. 
On the day 21, the inserts with Caco-2 monolayers were transferred on the plates with 
differentiated THP-1 cells. Inflammation was induced by 24 h incubation with 10 µg/ml of LPS on 
the basolateral compartment. Normal co-cultures (non-inflamed) were used as controls. 
2.6.2 Monitoring of barrier integrity by TEER 
The transepithelial electrical resistance (TEER) of Caco-2 culture and co-culture were 
measured with an epithelial voltohmmeter (Millicell-ERS-electrode, MERSS00001, Millipore 
Millicell; Billerica, MA, USA). TEER values were normalized subtracting the resistance of empty 








TEER value around 350-400 Ω·cm2 were used for the experiments. TEER of co-cultures were 
measured 4 and 24 h post inflammation induction.  
2.6.3 Anti-inflammatory and antioxidant activity on co-cultures 
Anti-inflammatory and antioxidant activity of Dex-NP on inflamed co-cultures were determined 
by measuring the production of IL-8 and TNF- in the apical and basolateral compartments, and 
the ROS production on differentiated THP-1 cells, respectively. Briefly, Dex-nanoparticles at 20 
µg/ml Compritol-1.7 µg/ml Dex and free Dex 1.7 µg/ml were applied on the apical compartment 
and at the same time LPS was added to the basolateral compartment. Upon 24 h of incubation 
at 37°C, supernatants of apical and basolateral compartments were collected and stored at -20°C 
for further analysis of cytokines by ELISA as stated above. On the other hand, the generation of 
ROS was measured on THP-1 cells using the carboxy-H2DCFDA dye as stated above. Besides, 
TEER was measured before and 4h and 24 h upon incubation.  
Inflamed co-cultures were also incubated with Dex-NP previously submitted to a digestion 
process. Briefly, 0.1 ml of nanoparticles were incubated with 0.9 ml of SGF at 37ºC for 30 min in 
an orbital shaker. After that, pH was adjusted to 6.8 using 1 M NaHCO3. Then 1 ml of SIF was 
added and incubated during 2 h.  
2.6.4 TEM 
Upon incubation, Caco-2 monolayers were analysed by TEM. Briefly, the monolayer was 
washed with 2 ml of washing buffer (0.1 M cacodylate - 0.1 M sucrose, pH 7.4) for 15 min and 
cells were fixed with 2.5% glutaraldehyde for 4 h at 4ºC. Then, monolayers were washed twice 
with PBS for 15 min and samples were postfixed with 1% OsO4 in 0.1 M PBS. Cells were 
dehydrated using a graded ethanol series and acetone and embedded in durcupan resin. 
Ultrathin sections of 70 nm, perpendicular to the filter plane, were cut using a Reichert-Jung 
Ultracut E Ultramicrotome, stained with uranyl acetate, and examined with a Zeiss EM109T 
transmission electron microscope using an acceleration voltage of 120 kev and images were 
recorded with a Gatan ES1000W digital camera.  
2.6.5 Immunofluorescence staining  
Upon incubation, the F-actin cytoskeleton, and nuclei of Caco-2 monolayers were stained with 
TOPRO3 and rhodamine-labeled phalloidin, respectively. Briefly, monolayers were washed with 
PBS and fixed overnight with 4% formaldehyde. Then, cells were permeabilized with 0.05 % Triton 
X-100 in PBS for 10 min, followed by 1h incubation with 3 % bovine serum albumin (BSA) in PBS. 
Finally, cells were incubated with rhodamine phalloidin (1:1000) and TOPRO3 (1:1000) in 1% 
BSA in PBS for 1 h at 37 °C. After staining the samples were mounted on slides using mowiol 
mounting medium. Image acquisition was performed by using a FluoView FV1000 confocal 
microscope (Olympus, Tokyo, Japan) equipped with a Plapon 60X/1.42 objective. 
2.7 Statistical analysis 
Statistical analysis was performed by one-way analysis of variance followed by Dunnet’s or 
Tukey test using Prisma 4.0 Software (Graph Pad, San Diego, California). p-value of < 0.05 was 
considered statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s. 
represents not significant (p > 0.05). 
3. Results 
3.1 Characterization of BR extract from H. tebenquichense 
TLC analysis of BR extract showed 5 spots and the UV-vis spectroscopy revealed the typical 
three-fingered profile of BR and its derivatives with absorption peaks at 455-460, 490, and 525 
nm and two cis absorption maxima at 385 and 405 nm (data not shown). HPLC profile showed 
16 peaks, each of them displaying the typical three-fingered spectrum of carotenoids (Fig. 1SA). 
The HPLC peaks with retention times from 64.26 to 85 min could be BR (with maximum 
absorbance peaks at 461-469, 483-495 and 516-528 nm) (Fig. 1SB, C and D), and different 
retention times being ones of the different isomers of BR as reported by Naziri et al., 2014 [34]. 
The HPLC peaks with retention times from 91.84 to 104.95 min were compatible with lycopene 
(with maximum at 441, 465 and 498 nm, Fig. 1SE) as reported [34].   
3.2 Structural features of Dex-NP 
NAC were prepared from NLC by replacing Miglyol by BR extract and SPC by PA. Structural 
features of void and Dex-NP are shown in Table 1. Remarkably, the size of NAC was nearly four 
folds lower than NLC (~ 66 nm vs ~250 nm). The presence of PA in NAC was responsible for the 
high negative  potential compared to NLC (-32 mV vs -11 mV). Dex did not cause significative 
changes in size, PDI and  potential compared to void NP. When loaded into NLC and NAC, the 
intrinsic solubility of Dex in aqueous media (71 ± 12 μg/ml) was increased by 18 and 17- folds 
respectively. The encapsulation efficiency was 76 ± 12% and 72 ± 23 % for NLC-Dex and NAC-








the presence of Miglyol and BR extract within the NLC and NAC core, respectively increased the 
Dex content by nearly 1.5-folds. It has been widely described that the less ordered matrix created 
by the inclusion of liquid lipid into de solid matrix increases the encapsulation efficiency of 
nanostructured lipid carriers as compared with solid lipid nanoparticles [35]. The broad standard 
deviation of the Dex content of NAC-Dex could be as consequence of the small size of the core.  
TEM images of NAC (Fig. 1SF) and NLC showed irregular shape NPs of roughly 50-60 nm 
and 100-150 nm mean diameter, respectively. Irregular shape NPs observed by TEM has been 
also described by other works [36, 37]. It is well known that during observation of soft 
nanoparticles by conventional TEM, the electron beam might modify the shape or even fuse the 
particles if the observation is not carried out under low dose conditions, producing artefacts that 
could be misinterpreted. Because of this, then, we analysed NAC structure by cryo-EM, as it is a 
very well-known technique for characterization of soft lipid nanoparticles. Cryo-EM images of NAC 
showed different morphologies that varied with the observation angle, such as ~ 100 nm circles, 
elongated ellipsoids of low electron density, or ~ 50 nm, needle like shapes of higher electron 
density (Fig. 1SG). DSC analysis showed a 11.7 and 13.1 °C reduction on the melting point of 
Compritol for Compritol/Miglyol and Compritol/BR extract mixtures, respectively (Table 1S). A 
further reduction of 2.5 and 4.4°C on the melting point was observed for NLC, and NAC, 
respectively. Crystallinity of Compritol was significantly reduced when formulated as NAC but not 
as NLC, as observed by the lower R.I. for NAC compared with Compritol/BR extract mixtures.  
The antioxidant activity of BR extract and NAC was determined using the DPPH radical 
scavenging assays. The scavenging capacities were linearly dependent on BR concentration, 
while NLC showed no antioxidant activity. The highest RSA (90 %) was observed at the maximum 
concentration of BR test (10 µg/ml). BR extract and NAC showed similar antioxidant activity (IC50: 
4.8 µg/ml) that was higher than for the standard Trolox (IC50: 7.1 µg/ml). Similar antioxidant 
activity was reported for BR extracts from Haloterrigena sp. (IC50: 4.5 µg/ml for DPPH assay) 
[24]. 
 
3.3. Stability under gastrointestinal conditions  
Size retention and lipolytic percentage of Dex-NP incubated in SGF and SIF were determined. 
SGF and SIF showed a wide peak of 600 nm mean size. Upon incubation, the 250 nm mean size 
of NLC was observed to be enlarged to a wide peak of 200-900 nm, suggesting aggregation upon 
interaction with gastrointestinal fluids. NAC in contrast, seemed not to be affected by SGF and 
SIF since two populations of 50-60 nm and 600 nm, corresponding to NAC and to the 
gastrointestinal fluids, respectively, were observed (Fig. 1A). Lipolysis of NLC, on the other hand, 
was almost completed within 30 min (Fig. 1B). In contrast, the lipolysis of NAC was significantly 
lower than of NLC, reaching an accumulative lipolytic percentage of 25-30% after 60 min. 
3.4 Cell viability and uptake 
The viability of differentiated THP-1 and Caco-2 cells after 24 h incubation with void and Dex-
NP, as determined by MTT, is shown in Fig. 2 A. It was found that the viability of THP-1 and Caco-
2 cells did not significantly decrease upon incubation with Dex at all the concentration tested, and 
void or Dex-NP between 20 and 200 μg/ml of Compritol after 24 h. A higher Compritol 
concentration (2000 μg/ml) of both Dex-NP led to significant viability loss of 80% for both cell 
types.  
The uptake of C6-labeled NPs by Caco-2 and differentiated THP-1 cells as measured by flow 
cytometry along 5 h, is shown in Fig. 2 B and C. NAC-C6 but no NLC-C6 were highly uptaken by 
Caco-2 cells. Both types of NPs were uptaken by differentiated THP-1 cells, but the extent of 
uptake was higher for NAC than for NLC. At 5 h, NAC-C6 uptake by differentiated THP-1 cells 
was 2-fold higher than of NLC-C6, while NAC-C6 uptake by Caco-2 cells was 4-fold higher than 
of NLC-C6. 
3.5 Anti-inflammatory and antioxidative activities and morphological changes on 
Caco-2/THP-1 co-cultures stimulated with LPS 
The effect of Dex-NP on a gut inflammation model, consisting of Caco-2 cells and 
differentiated THP-1 cells stimulated with LPS grown on the apical and basolateral side of cell 
culture inserts, respectively, was assessed. The model was characterized measuring IL-8 and 
TNF- release and intracellular ROS production, besides histology, immunohistochemistry and 
TEER measurement were performed before and after incubation with non-digested and digested 
Dex and Dex-NP. The inflamed co-culture released significant amounts of IL-8 in the apical 
compartment and TNF- in the basal compartment (Fig. 2SA), produced high amount of ROS 










In the non-inflamed co-cultured, the Caco-2 cells formed a polarized monolayer displaying 
microvilli (M) organized in brush borders and tight junctions in the apical zone (TJ), desmosomes 
(D) and interdigitations (I) (finger shaped cell membrane folding between cells, characteristic 
features of epithelial cells) (Fig. 3SA). The F-actin was longitudinally aligned in the cell periphery, 
forming the characteristic actin belt observed in adjacent epithelial cells (Fig. 4SA). The 
inflammation caused morphological changes. Although the monolayer was continuous, displaying 
D and I, the number, extent, and organization of M decreased, and no TJ were observed (Fig. 
3A). Actin microfilaments were disorganized, with a significant reduction in intracellular F-actin, 
as judged by the decreased fluorescence at the level of the peripheral actin belt (Fig. 4SBiii). 
TNF- disrupts the assembly of F-actin, which is normally found intercellularly along the edge of 
the cell. The decreased F-actin is associated with TJ disruption and increased permeability of 
epithelial barriers [38]. In sum, the typical pathophysiological changes observed in the in vivo 
inflammatory state, such as morphological changes, increased production of pro-inflammatory 
cytokines and decreased epithelial barrier function were reproduced in the co-culture model. In 
there, Dex had no effect on cytokine release, but Dex-NP reduced the release of proinflammatory 
cytokines and reverted the morphological changes induced by LPS. Both NLC-Dex and NAC-Dex 
showed comparable anti-inflammatory activity, reducing by ~ 65 and 55 % the release of TNF- 
and IL-8, respectively (Fig. 4A) but only NAC-Dex decreased by 60 % the induction of ROS (Fig. 
4B).  
On the other hand, Dex did not increased the TEER (~200 Ω*cm2) (Fig. 4C) and partly reverted 
the morphological changes of inflammation: if well the TJ were well defined and showed I, no D 
were observed, and low amounts of M were detected (Fig.  3SBiii, Table 2S). NLC-Dex, neither 
increased the TEER (~240 Ω*cm2) and partly reverted the damages observed in M. Intercellular 
spaces and F-actin disassembly were observed, resulting in loss of tight assembling, although 
the D remained present (Fig. 3SBii, 4SBi). On the contrary, NAC-Dex increased the TEER (~300 
Ω*cm2) and reverted the damages in M; as a result, the structural organization resembled that of 
the non-inflamed model: well defined TJ, I, D (Fig. 3B) and F-actin filaments  (Fig. 4SBii). 
Finally, after submitting to a simulated gastrointestinal digestion, NLC-Dex completely lost 
its ability to reduce the release of proinflammatory cytokines. In contrast, NAC-Dex partly retained 
it, as judged by the 30 % and 70 % reduction in TNF- and IL-8 release respectively, while it 
slightly reduced the production of ROS and increased the TEER (Fig. 4 A, B and C). 
 
4. Discussion 
BR displays promising beneficial activities at multiple cell levels; nonetheless, its therapeutic 
use is not popular yet. This is probably because of its physical chemistry lability and 
hydrophobicity, and because the identification of extremophiles as novel sources of biomaterials 
has occurred much later than that of green algae and their astaxanthins [25, 39]. The high content 
of BR and derivatives found in the H. tebenquichense acetone soluble fraction used in this work, 
was in line with the reported abundance of BR and derivatives produced by the Halorubrum genus 
[18, 23, 34]. The structure of labile molecules can be preserved on the other hand, by avoiding 
oxidation and protecting them from the GI environment if properly formulated as micro- or nano-
particles. Surprisingly however, only a single work has reported the preparation of oil-in-water 
(o/w) micro- and nanoemulsions of BR [40]. Besides, no GI stability or interaction with intestinal 
cells was assessed. Here the structural features of novel NPs covered with PA, containing BR 
and Dex in the core, together with their effect on a gut inflammation model, are presented. Due 
to the presence of PA, NAC-Dex exhibited ultra-small size (66 nm), negative  potential (-31.5 
mV), were stable under gastrointestinal conditions, and showed high cell uptake by both 
macrophages (THP-1 cells) and by enterocytes (Caco-2 cells). PA is a mixture of the sn 2,3 ether 
linked phytanyl saturated archaeolipids: phosphatidylglycerophosphate methyl ester (PGP-Me), 
sulphated diglycosyl diphytanylglycerol diether (SDGD), phosphatidylglycerol (PG) and 
bisphosphatidyl glycerol (BPG) [16]. As already described by Higa et al., [27], PGP-Me and BPG 
with two, and PG with one, phosphate groups negatively charged at physiological pH are 
responsible for the strong negative surface charge, a fact that leads to the lower sized NAC-Dex 
compared with NLC-Dex. On the other hand, because of their structure, PA are resistant to 
hydrolysis, oxidation and stereospecific phospholipases [41]; hence PA content was responsible 
of the higher stability under gastrointestinal conditions of NAC-Dex compared with NLC-Dex. 
Additionally, as PGP-Me is a ligand of SRA1 mainly express on macrophages, PA presence on 
NAC-Dex was responsible for their superior uptake by THP-1 cells compared with NLC-Dex. In 
the case of Caco-2 cells, the smaller size of NAC-Dex could contribute to the higher uptake than 








larger number of nanoparticles interacting with cell membrane area, and consequently higher 
efficiency of cellular uptake.  
The most relevant effects of NAC-Dex, however were observed on a gut inflammation model. 
In vitro models that adequately reproduce both healthy and inflamed intestinal tissue are useful 
tools for studying mechanisms of intestinal inflammation and new therapeutic drugs. Here, we 
tested the anti-inflammatory and antioxidant activity of Dex-NP on a co-culture of Caco-2 and 
PMA-differentiated LPS stimulated THP-1 that mimics the intestine in inflamed state [44, 45]. This 
model showed typical pathophysiological changes observed in the state of inflammation in vivo: 
release of TNF- by macrophages, IL-8 by epithelial cells, increased permeability, decreased 
number and length of epithelial M and reduced number of TJ. We observed that NLC-Dex and 
NAC-Dex displayed higher anti-inflammatory activity than that of Dex. The higher uptake by THP-
1 cells, however, was not correlated with the anti-inflammatory activity of NAC-Dex  that was 
comparable to that of NLC-Dex, probably because NAC-Dex were not optimized for delivering 
Dex to its cell cytoplasmic receptor, as occurred with Dex-loaded pH-sensitive formulations [16]. 
However, only NAC-Dex reduced ROS production and produced a reversion on morphological 
changes induced by inflammation and partial reconstituted the barrier function of the co-culture, 
that was absent for NLC-Dex and Dex. The barrier function of the intestinal epithelium is 
maintained partly by TJs between adjacent epithelial cells. TNF-, produced mainly by activated 
macrophages, monocytes and T cells, caused TJ disruption both through increased Myosin Light 
Chain Kinase protein expression and subsequent disassembly of F-actin and decreased ZO-1 
expression [38]. Since both NLC-Dex and NAC-Dex reduced TNF- and IL-8 release, it could be 
speculated, that the antioxidant activity together with massive internalization of NAC-Dex into 
Caco-2 cells would help to restore the barrier function. It cannot be discarded hence that the 
uptake of archaeolipids may finally play a role in the observed barrier repair activity of NAC-Dex.  
Concluding, the result suggested that the anti-inflammatory activity was not the only factor 
needed to restore the function of this experimental epithelial barrier, and that NAC-Dex may be 
an excellent candidate deserving deeper exploration as intestinal barrier repairing agent. 
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Fig 1. Stability of nanoparticles in simulated gastrointestinal fluids. (A) Colloidal stability of in 
simulated gastric (SGF) and intestinal fluids (SIF). (B) Lipolysis percentage versus time profiles 
of NLC and NAC titrated by NaOH at a constant pH of 6.8. Data is expressed as mean ± SD 
(n=3).  
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Fig. 2. Cell viability and cellular uptake. (A) Viability upon 24 h incubation with Dex, NLC, NLC-
Dex, NAC and NAC-Dex, evaluated by MTT on Caco-2 cells and THP-1 cells (n=3). Kruskal-
Wallis multiple comparisons test. Asterisks indicate significant differences between groups and 
control. (B) Normalized C6 fluorescence intensity of Caco-2 cells and (C) differentiated THP-1 
cells after 1, 3 and 5 hours of incubation with C6-labeled nanoparticles. Values are expressed as 
mean ± SD (n=3).  
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Fig. 3. Ultrathin sections of Caco-2 cells co-cultured with PMA differentiated LPS stimulated THP-
1 cells analyzed by transmission electron microscope. (A) Control cells treated with culture 










































Fig. 4.  Anti-inflammatory, antioxidant activity and TEER values on the gut inflammation model 
upon treatment with Dex and Dex-NP. (A) Pro-inflammatory cytokines release. Each cytokine 
level was normalized with respect to the level induced by LPS. (B) Fluorescence intensity of 
carboxy-DCFDA normalized with respect to LPS treated co-cultures. (C) TEER values co-cultures 
before and 24 h after treatments. Values are expressed by mean value ± S.D (n = 3) and analysed 
using a one-way ANOVA compared with LPS. Dex and Dex-NP were (+) digested with 
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ζ Potential (mV 
± SD) 
Dex or C6 
(µg/ml ± SD) 
NLC 255.5 ± 31.7 0.223 ± 0.067 -13.4 ± 3.7 
- 
NAC 61.4 ± 9.7 0.355 ± 0.122 -32.5 ± 5.4 
- 
NLC-Dex 251.1 ± 41.8 0.190 ± 0.041 -13.2 ± 9.8 1269 ± 254 
NAC-Dex 66.2 ± 15.0 0.346 ± 0.093 -31.5 ± 5.8 1208 ± 479 
NLC-C6 196.5 ± 29.9 0.198 ± 0.062 -18.0 ± 2.1 66 ± 5.5 
NAC-C6 52.0 ± 10.8 0.347 ± 0.171 -32.7 ± 6.0 72 ± 0.8 
Data are expressed as mean ± standard deviation (SD) from five independent batches. 
NLC: ordinary nanostructured lipid carriers; NAC: nanostructured archaeolipid carriers; Dex: 
dexamethasone; NLC-Dex and NAC-Dex: dexamethasone loaded NLC and NAC, respectively; 
NLC-C6 and NAC-C6: coumarin 6 loaded NLC and NAC, respectively. SD: Standard Deviation, 
PDI: Polydispersity Index. 
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